Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500
Debt
Debt-to-Equity Ratio0.96
Current Ratio2.34
Quick Ratio2.32
Price-To-Earnings
Trailing P/E Ratio94.40
Forward P/E Ratio43.17
P/E Growth1.69
Sales & Book Value
Annual Sales$141.10 million
Price / Sales37.06
Cash Flow$3.8544 per share
Price / Cash64.29
Book Value$18.94 per share
Price / Book13.08
Profitability
EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins52.10%
Return on Equity25.95%
Return on Assets12.52%
Miscellaneous
Employees39
Outstanding Shares21,100,000
Market Cap$5.12 billion
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) posted its quarterly earnings results on Monday, August, 6th. The biotechnology company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.34 by $0.25. The biotechnology company had revenue of $90 million for the quarter, compared to analyst estimates of $82.20 million. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. Ligand Pharmaceuticals's revenue for the quarter was up 221.4% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals issued an update on its FY18 earnings guidance on Monday, August, 6th. The company provided EPS guidance of ~$6.30 for the period, compared to the Thomson Reuters consensus estimate of $6.21. The company issued revenue guidance of ~$232 million, compared to the consensus revenue estimate of $227.36 million.
What price target have analysts set for LGND?
7 equities research analysts have issued 1 year price targets for Ligand Pharmaceuticals' shares. Their predictions range from $105.00 to $260.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $214.8333 in the next twelve months. This suggests that the stock has a possible downside of 11.5%. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and are raising our price target to $239 from $182. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 165 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales and collaborative revenue. Below we show our updated clinical NPV valuation model, which accounts for updates to the ‘Next 12’ assets as well as progress for the later stage assets included." (6/28/2018)
- 2. According to Zacks Investment Research, "Ligand’s earnings and sales beat estimates in the first quarter of 2018. The company’s Captisol Formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could generate future licensing opportunities. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these products could have a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (6/6/2018)
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX) and Bausch Health Companies (BHC).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 48)
- Mr. Matthew W. Foehr, Pres & COO (Age 45)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Ms. Audrey Warfield-Graham, Sr. VP of HR
Has Ligand Pharmaceuticals been receiving favorable news coverage?
Headlines about LGND stock have trended somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a media and rumor sentiment score of 0.21 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.69 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Ligand Pharmaceuticals.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.33%), Janus Henderson Group PLC (4.35%), Victory Capital Management Inc. (2.52%), Renaissance Technologies LLC (2.48%), Bank of New York Mellon Corp (2.42%) and Conestoga Capital Advisors LLC (2.36%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Impax Asset Management LLC, CIBC Private Wealth Group LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, Rice Hall James & Associates LLC, Glenmede Trust Co. NA and Dimensional Fund Advisors LP. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Janus Henderson Group PLC, Federated Investors Inc. PA, Conestoga Capital Advisors LLC, Hood River Capital Management LLC, Victory Capital Management Inc. and OppenheimerFunds Inc.. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $242.65.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $5.12 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
